Sankyo Pharma GmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

Active:13

Completed:9

Trial Phases

4 Phases

Phase 1:4

Phase 2:1

Phase 3:7

+1 more phases

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 3

7 (53.8%)

Phase 1

4 (30.8%)

Phase 2

1 (7.7%)

Phase 4

1 (7.7%)

Olmesartan Medoxomil and Diabetic Nephropathy

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus
Diabetic Nephropathy
Proteinuria
Renal Disease

First Posted Date: 2006-08-15

Last Posted Date: 2006-10-09

Lead Sponsor: Sankyo Pharma Gmbh

Target Recruit Count: 300

Registration Number: NCT00362960

Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension

Phase 4

Completed

Conditions: Essential Hypertension

Interventions: Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary

First Posted Date: 2006-04-05

Last Posted Date: 2010-12-10

Lead Sponsor: Sankyo Pharma Gmbh

Target Recruit Count: 694

Registration Number: NCT00311155

Locations: 🇦🇹
University Klinik, F. Innere Medizin, Innsbruck, Austria
🇦🇹
Diakonissen-Krankenhaus Hospital, Salzburg-Aigen, Austria
🇧🇪
Centre Hospitalier du Bois de l'Abbaye et de Hesba, Department of Intensive Care, Seraing, Belgium

and more 37 locations